Complementary Role of 68Ga-Prostate-Specific Membrane Antigen and 18F-FDG PET/CT for Evaluation of Metastases and Treatment Response in Renal Cell Carcinoma.
Aged
Carcinoma, Renal Cell
/ diagnostic imaging
Edetic Acid
/ analogs & derivatives
Fluorodeoxyglucose F18
Gallium Isotopes
Gallium Radioisotopes
Humans
Kidney Neoplasms
/ diagnostic imaging
Male
Middle Aged
Neoplasm Metastasis
Oligopeptides
Positron Emission Tomography Computed Tomography
Treatment Outcome
Journal
Clinical nuclear medicine
ISSN: 1536-0229
Titre abrégé: Clin Nucl Med
Pays: United States
ID NLM: 7611109
Informations de publication
Date de publication:
01 Jul 2021
01 Jul 2021
Historique:
pubmed:
31
3
2021
medline:
22
6
2021
entrez:
30
3
2021
Statut:
ppublish
Résumé
We present a case of clear cell renal cell carcinoma, which demonstrates complementary FDG and prostate-specific membrane antigen (PSMA) uptake on metastases in PET/CT, as an example of tumor heterogeneity. The patient had non-FDG-avid lung and bone metastases with PSMA uptake, whereas metastatic cervical and axillary lymph nodes showed vice versa, and skeletal muscle metastasis to vastus lateralis, which is an unusual region for metastasis, showed both PSMA and FDG positivity. In response assessment, mix response was detected. It seems that 68Ga-PSMA and 18F-FDG may have a complementary role in demonstration of metastasis accurately and assessment of treatment response in clear cell renal cell carcinoma.
Identifiants
pubmed: 33782292
doi: 10.1097/RLU.0000000000003590
pii: 00003072-202107000-00011
doi:
Substances chimiques
Gallium Isotopes
0
Gallium Radioisotopes
0
Oligopeptides
0
gallium 68 PSMA-11
0
Fluorodeoxyglucose F18
0Z5B2CJX4D
Edetic Acid
9G34HU7RV0
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
579-581Informations de copyright
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.
Déclaration de conflit d'intérêts
Conflicts of interest and sources of funding: none declared.
Références
Ricketts CJ, Linehan WM. The origin, evolution and route to metastasis of clear cell RCC. Nat Rev Nephrol . 2018;14:538–540.
Chen R, Zhou X, Huang G, et al. Fructose 1,6-bisphosphatase 1 expression reduces 18 F-FDG uptake in clear cell renal cell carcinoma. Contrast Media Mol Imaging . 2019;2019.
Raveenthiran S, Esler R, Yaxley J, et al. The use of 68 Ga-PET/CT PSMA in the staging of primary and suspected recurrent renal cell carcinoma. Eur J Nucl Med Mol Imaging . 2019;46:2280–2288.
Chen E-J, Tan TH, Chew MT, et al. 68 Ga-PSMA PET/CT and 18 F-FDG PET/CT in renal cell carcinoma. Clin Nucl Med . 2020;45:e317–e319.
Evangelista L, Basso U, Maruzzo M, et al. The role of radiolabeled prostate-specific membrane antigen positron emission tomography/computed tomography for the evaluation of renal cancer. Eur Urol Focus . 2020;6:146–150.
Pozzessere C, Bassanelli M, Ceribelli A, et al. Renal cell carcinoma: the oncologist asks, can PSMA PET/CT answer? Curr Urol Rep . 2019;20:68.
Shuch B, Amin A, Armstrong AJ, et al. Understanding pathologic variants of renal cell carcinoma: distilling therapeutic opportunities from biologic complexity. Eur Urol . 2015;67:85–97.
Serie DJ, Joseph RW, Cheville JC, et al. Clear cell type A and B molecular subtypes in metastatic clear cell renal cell carcinoma: tumor heterogeneity and aggressiveness. Eur Urol . 2017;71:979–985.
Sasikumar A, Joy A, Nanabala R, et al. Complimentary pattern of uptake in 18 F-FDG PET/CT and 68 Ga–prostate-specific membrane antigen PET/CT in a case of metastatic clear cell renal carcinoma. Clin Nucl Med . 2016;41:e517–e519.
Taira H, Ishii T, Inoue Y, et al. Solitary psoas muscle metastasis after radical nephrectomy for renal cell carcinoma. Int J Urol . 2005;12:96–97.